Ardelyx, Inc. (ARDX) Stock

Ardelyx, Inc. (ARDX) is a Healthcare stock trading at $6.03 (as of 2026-06-18), with a market capitalization of $1.34B and a trailing P/E of -25.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapies focused on gastrointestinal and cardiorenal conditions. Its lead program, tenapanor, is being studied for IBS with constipation and for controlling serum phosphorus in adults with CKD on dialysis, and it is developing additional candidates including RDX013 and RDX020.

Valuation — source: SEC EDGAR (first-party)
Price$6.03
Market Cap$1.34B
P/E Ratio-25.2
EV / EBITDA-49.0
Price / Book10.06
Price / Sales3.49
DCF Value (model)$-3.60
DCF Upside vs Price-159.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$407.32M
Net Margin-15.1%
Return on Equity-39.1%
Debt / Equity1.37
Current Ratio3.49
Revenue Growth (YoY)27.5%
EPS Growth (YoY)-11.8%
FCF Growth (YoY)-16.7%
Financial Health — source: SEC EDGAR
Altman Z-Score1.25 (distress)
Piotroski F-Score3/9 (weak)
Valuation vs Sector & Industry
Stock P/E-25.2
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-220.3%
vs Industry-246.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($126.77M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMichael G. Raab
Employees395
CountryUS
IPO Date2014-06-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Precigen, Inc. (PGEN)
  • Oruka Therapeutics, Inc. (ORKA)
  • Relay Therapeutics, Inc. (RLAY)
  • Collegium Pharmaceutical, Inc. (COLL)
  • Rapport Therapeutics, Inc. Common Stock (RAPP)
  • MBX Biosciences, Inc. Common Stock (MBX)
  • Tyra Biosciences, Inc. (TYRA)
  • Immatics N.V. (IMTX)
ARDX earnings history · ARDX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.